ALTUVIIIO
RegulatoryapprovedALTUVIIIOPositive
AI Analysis
Summary
ALTUVIIIO, a recombinant human coagulation factor VIII-Fc fusion protein, has been FDA approved for treating Hemophilia A in adults and children for routine prophylaxis, on-demand treatment, and perioperative management of bleeding episodes.
Outcome Details
FDA approval for treatment of Hemophilia A in adults and children
Importance:8/10
Sentiment:
0.80
FDA approvalHemophilia AFactor VIIIProphylaxisRare disease
Related Companies
Read the original article
Published by FDA Biologics (BLA & Biosimilars) on August 26, 2026 1:02 PM